Navigation Links
ViroPharma to Present at the BIO CEO & Investor Conference
Date:2/5/2008

EXTON, Pa., Feb. 5 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, chief financial officer and chief operating officer of ViroPharma, will present at the BIO CEO & Investor Conference at 12:30 P.M. ET on Monday, February 11, 2008. The conference is being held at the Waldorf=Astoria, in New York.

ViroPharma's presentation will be webcast live for investors through http://www.viropharma.com and available through February 28, 2008.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
4. Avicena Group to Present at Noble Financial Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CEL-SCI to Present at the Noble Financial Conference
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Strategic Diagnostics Updates Roth Conference Presentation Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... BARCELONA, Spain , April 27, 2015  Together ... during the 3rd ESTRO Forum in Barcelona ... Hope, a nonprofit organization with the mission to improve ... Radiating Hope believes that no patient should ... is not affordable. Consequently, it cooperates with hospitals and ...
(Date:4/24/2015)... 24, 2015 Leading Regenerative Veterinary ... its allogeneic stem-cell product development program and changes ... the corporate strategic direction. , “I am extremely ... stem cell development program has been kicked into ... manufacturing facility and hiring of our new Director ...
(Date:4/24/2015)... , April 24, 2015  Navitas Life Sciences is delighted ... Head of Clinical and Regulatory Services. Shalabh is a proven ... co-founder and CEO of Kinapse, as well as a Strategy ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... commented "I am delighted to welcome Shalabh into this ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
Breaking Biology Technology:Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... Announces Revised Operating Plan to Respond to NEBIDO Delay, ... IDEV ) today announced that it has received,an ... (FDA) for,NEBIDO(R) related to a New Drug Application (NDA) ... on June 27, 2008, indicated that the,application may be ...
... Company to Commercialize ... Novel Technology from UC Davis, BOSTON, ... early stage university business ventures, has,established RF Biocidics, Inc., to ... UC Davis., The newly formed RF Biocidics, Inc. is ...
... 30 Raptor,Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), ... private placement of 20 million units,constituting an aggregate ... and two-year warrants to purchase 10 million shares ... Company raised $9.3 million in,net proceeds from the ...
Cached Biology Technology:Indevus Receives Approvable Letter from FDA for NEBIDO(R) 2Indevus Receives Approvable Letter from FDA for NEBIDO(R) 3Indevus Receives Approvable Letter from FDA for NEBIDO(R) 4Indevus Receives Approvable Letter from FDA for NEBIDO(R) 5Indevus Receives Approvable Letter from FDA for NEBIDO(R) 6Indevus Receives Approvable Letter from FDA for NEBIDO(R) 7Allied Minds Launches Novel Disinfectant/Disinfestant Technology Start-up With UC Davis 2Raptor Pharmaceuticals Closes $10 Million Private Placement 2Raptor Pharmaceuticals Closes $10 Million Private Placement 3Raptor Pharmaceuticals Closes $10 Million Private Placement 4
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... an increasing health problem all over the world. Bacteria ... pharmaceuticals that can combat this threat are in great ... chemical compound in the garlic plant that neutralises resistant ... demonstrates that ajoene the substance present in garlic ...
... as a way to represent the impact of human ... industry over the last two decades. Since the ... it was introduced by researchers William E. Rees and ... a range of complicated phenomena as a single metric, ...
... Mosaic , a new digital publication dedicated to exploring the ... 2014. Mosaic will carry long-form features, articles ... its impact on society. All articles will be free to ... Commons licence so that it can be reproduced and distributed ...
Cached Biology News:Garlic counteracts virulent bacteria 2What good are footprints? 2What good are footprints? 3New digital publication Mosaic explores the science of life 2
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
...
Biology Products: